PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33273169-7	2020	Agents such as the Bruton tyrosine kinase (BTK) inhibitor ibrutinib or immunomodulatory drugs such as lenalidomide and pomalidomide have shown promising response rates in the relapsed setting.	Lenalidomide	102-114	Bruton tyrosine kinase	Homo sapiens	43-46	
25984532-6	2015	Future efforts should aim at targeting the role of NF-kappaB resistance in clinical trials, where novel agents like lenalidomide and proteasome inhibitors with established activity in this perspective will be an important component in combination therapy, along with new monoclonal antibody, BTK-inhibitors, and other novel therapy agents.	Lenalidomide	116-128	Bruton tyrosine kinase	Homo sapiens	292-295	
30423172-3	2019	Agents like the Bruton tyrosine kinase (BTK) inhibitor ibrutinib or immunomodulatory drugs (IMiDs) like pomalidomide and lenalidomide have shown promising high response rates in the salvage setting.	Lenalidomide	121-133	Bruton tyrosine kinase	Homo sapiens	16-38	
30423172-3	2019	Agents like the Bruton tyrosine kinase (BTK) inhibitor ibrutinib or immunomodulatory drugs (IMiDs) like pomalidomide and lenalidomide have shown promising high response rates in the salvage setting.	Lenalidomide	121-133	Bruton tyrosine kinase	Homo sapiens	40-43	
22698399-5	2012	Blockade of B cell receptor signaling using the BTK inhibitor ibrutinib also downregulates IRF4 and consequently synergizes with lenalidomide in killing ABC DLBCLs, suggesting attractive therapeutic strategies.	Lenalidomide	129-141	Bruton tyrosine kinase	Homo sapiens	48-51	
22975686-0	2013	BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-kappaB.	Lenalidomide	85-97	Bruton tyrosine kinase	Homo sapiens	0-3